Solid Serous Cystadenoma of the Pancreas: A Case Report of 2 Patients Revealing Vimentin, β-Catenin, α-1 Antitrypsin, and α-1 Antichymotrypsin as New Immunohistochemistry Staining Markers

Wenming Wu, MD, Xiafei Hong, MD, Ji Li, MD, Menghua Dai, MD, Wenze Wang, MD, Anli Tong, MD, Zhaohui Zhu, MD, Hongmei Dai, MD, and Yupei Zhao, MD

Abstract: Solid serous cystadenoma (SCA) of the pancreas is a rare type of pancreatic solid tumors. Postoperative pathological evaluation is of particular importance for distinguishing solid SCA of the pancreas from other pancreatic solid tumors.

Here we present 2 cases of solid SCA of the pancreas, both preoperatively diagnosed with pancreatic neuroendocrine tumors. One case had positive OctreoScan test.

Surgical resections were done for both cases. Postoperative immunohistochemistry assays were conducted with marker panels for SCA and 2 types of pancreatic solid tumors, which were neuroendocrine tumor (pNET) and solid pseudopapillary tumor (SPT).

Two cases showed typical staining patterns for SCA markers. Notably, both cases showed positivity for 4 SPT markers (vimentin, β-catenin, α-1 antitrypsin, and α-1 antichymotrypsin).

Emphasis should be paid to those 4 new markers for future pathological diagnosis of solid SCA of the pancreas.

(Medicine 94(12):e644)

Abbreviations: IHC = immunohistochemistry, PAS = periodic acid–Schiff, pNET = pancreatic neuroendocrine tumor, SCA = serous cystadenoma, SPT = solid pseudopapillary tumor, SSCA = solid-type serous cystadenoma.

INTRODUCTION

Serous cystadenoma (SCA) of pancreas accounts for more than half of cyst-forming neoplasms and has been increasingly recognized with advancement of clinical imaging evaluations.1 Its biological behavior is benign compared with other types of cyst-forming neoplasms, including mucinous cystic neoplasms and intraductal papillary mucinous neoplasms. Under the light microscope, tumor cells of SCA are polygonal in shape with small round nuclei and clear or pale cytoplasm, usually without mitosis or necrosis. The cytoplasm consists of glycogen granules, which are periodic acid–Schiff (PAS) positive but diastase sensitive. Tumor cells are organized in patterns of solid/nested, microcystic, or oligocystic architecture.2 Immunohistochemistry (IHC) typically shows positivity for epithelial marker protein cytokeratin 7/8/18/19 and epithelial mucin 1/6, α-inhibin.3

Solid-type serous cystadenoma (SSCA), which was originally designated by Perez-Ordonez et al.,4 is an extremely rare disease entity with only 15 cases reported so far.2 Apart from other subtypes of SCA with cyst morphology, SSCA is a solid pancreatic tumor. The preoperative diagnosis of SSCA is rather challenging and often misdiagnosed as other solid pancreatic tumors.3

Here we present 2 cases of SSCA. We screened the IHC markers for SCA and 2 types of solid pancreatic tumors that are solid pseudopapillary tumor (SPT) and pancreatic neuroendocrine tumor (pNET). Unexpectedly, 4 SPT markers were positive for both SSCA cases, which were vimentin, β-catenin, α-1 antitrypsin, and α-1 antichymotrypsin.

CLINICAL PRESENTATION

Case 1

A 48-year-old male presented with episodes of severe left abdominal cramps, without nausea and vomiting. The past medical history was significant for hypercholesterolemia and multiple kidney cysts. Physical examination was unremarkable. Preoperative contrast-enhanced computed tomography revealed a 2.7 cm, round mass in the head of the pancreas with enhancement in the arterial phase (Figure 1A) and 3 ring-enhancing masses in liver segments V and VIII ranging from 1.5 to 1.9 cm in diameter with obscure boundaries to the surrounding liver parenchymal. An OctreoScan test detected hot spots in the head of the pancreas and the right lobe of liver (Figure 1B). Based on the evidence of typical computed tomography imaging pattern and positive OctreoScan test, the preoperative diagnosis was pNET with probable liver metastasis. The patient underwent pyloric-preserving pancreaticoduodenectomy with cholecystectomy to resect the pancreatic tumor. However, the tumors in the liver were not resected because the patient insisted on not removing them. No subsequent radiotherapy or chemotherapy was conducted. Follow-up was conducted 2 years later...
showing no evidence of pancreatic tumor recurrence and the size of liver tumors were the same as previous.

Case 2

A 65-year-old female was found to have a $2.3 \times 1.8$ cm, round, arterial-phase enhancing mass in the body of the pancreas by computed tomography (Figure 1C and D). The past medical history was significant for breast cancer and hypertension. Physical examination was unremarkable. OctreoScan test was not conducted. The preoperative diagnosis was pNET, based on the typical computed tomography imaging pattern. The patient underwent laparoscopic spleen-preserving distal pancreatectomy, without subsequent radiotherapy or chemotherapy.

**METHODS**

**Ethical Approval**

This study was approved by the Institutional Review Board of the Peking Union Medical College Hospital, Beijing, China. Both patients signed the informed consents to approve the use of surgical specimen for research purposes.

**Staining Protocol**

The IHC staining was conducted in the Department of Pathology, Peking Union Medical College Hospital. The IHC markers were stained by automated IHC/ISH (immunohistochemistry/in situ hybridization) staining instrument (Ventana, Mountain View, CA, USA), according to the standardized protocol.

**PATHOLOGICAL ANALYSIS**

Both cases had firm, gray–pink, well-demarcated tumor masses with adjacent normal pancreas tissues harvested during the surgery. The tumor size of Case 1 measured $22 \times 18 \times 18$ mm (Figure 1E) and that of Case 2 measured $18 \times 10 \times 10$ mm. Histologically, both tumors consisted of cells with small round nuclei and clear cytoplasm (Figure 2A and B). Both tumors had solid area of nested cells, whereas other parts of the tumor showed microcystic morphology with cells of lobular architecture. Fibrous tissues could be seen between the tumors and the adjacent normal pancreas, and between the tumor nests and lobules. Both tumors were PAS positive and diastase sensitive. Immunohistochemistry assay was conducted with a list of markers, which could potentially differentiate SCA, pNET, and SPT. The SCA panel included cytokeratin 7/19, AE1/AE3, epithelial membrane antigen, and α-inhibin. The pNET included chromogranin A, synaptophysin, carcinomaembryonic antigen, and endocrine peptides (insulin, glucagon, serotonin, gastrin, calcitonin, and somatostatin). The SPT panels included CD56, CD10, vimentin, α-1 antitrypsin, α-1 antichymotrypsin, progesterone receptor, and β-catenin. Both cases showed positivity for all SCA panel markers and negativity for all pNET panel markers, except for the negativity of α-inhibin in Case 2 (Table 1). As for the SPT panels, both
cases showed strong positivity for vimentin on the basal membrane, weak positivity for the lateral membrane, and negativity on the apical membrane of the tumor cell, without cytoplasmic or nuclear staining (Figure 2C). Both cases showed strong positivity for β-catenin with membranous localization (Figure 2D). Both cases also showed positivity for α-1 antitrypsin and α-1 antichymotrypsin, which were localized primarily in cytoplasm of tumor cells and the lumen surrounded by tumor cells (Figure 2E and F). Both of them were negative for CD56, CD10, and progesterone receptor. The staining patterns mentioned above were similar in both solid and microcystic areas of the tumors.

**DISCUSSION**

SSCA is relatively rare compared with microcystic and oligocystic counterparts. The underlying pathophysiological and molecular differences among solid, microcystic, and oligocystic components are still unknown. Whole-exome sequencing of SCA has revealed only 10 somatic mutations for each SCA, much less than pancreatic adenocarcinoma.

The diagnosis of SCA is challenging by routine clinical imaging studies. The 2 cases in the present study demonstrated similar properties with pNET by contrast-enhanced computed tomography. Of note, 1 case even showed positivity for OctreoScan, which was thought as a specific study for neuroendocrine tumors with somatostatin receptors.

From our perspective, although preoperative biopsy is rarely done for suspected pancreatic neuroendocrine tumors, postoperative pathological confirmation of the definitive diagnosis is a routine practice.

SCA carries good prognosis. Either surgery or observation is acceptable for SCA, and no further targeted or chemotherapy is necessary.1 Targeted therapy, such as everolimus, is an option for advanced pNET.2

The pathological examination and staining patterns in these 2 cases were typical for SSCA. The markers for pNET were exclusively negative, which demonstrated that pathological workup could serve as a reliable tool to differentiate SCA from pNET. Unexpectedly, SPT markers (vimentin, β-catenin, α-1 antitrypsin, and α-1 antichymotrypsin) were positive in these 2 cases. Vimentin is a type of intermediate filament and a marker for mesenchyme cell origin. Previous studies demonstrated that vimentin played a role in epithelial to mesenchymal transitions.13 The typical staining pattern of vimentin for SPT is cytoplasmic and membranous localization.2 SCA was originally considered to be stained negative for vimentin.3 However, a recent case report suggested membranous vimentin positivity for microcystic SCA. The 2 cases showed similar pattern of membranous vimentin positivity in both the cases. The membrane-localized β-catenin functions as a member of E-cadherin–β-catenin–α-catenin complex for cell–cell adhesion, whereas the nuclear-localized counterparts alter gene expression and are involved in epithelial to mesenchymal transitions.15 The typical staining pattern of β-catenin in SPT was nuclear and cytoplasmic.16 We demonstrate that, in contrast to SPT, the β-catenin is exclusively stained positive on the membrane of SCA. α-1 antitrypsin and α-1 antichymotrypsin are both acute-phase proteins, which are focally positive in SPT.17 The 2 cases of SCA showed cytoplasmic localization of the 2 markers, and more significantly, the lumen of the SCA also showed positive stain. This indicates that α-1 antitrypsin and α-1 antichymotrypsin may be produced by and secreted from the tumor cells of SCA.

We admitted that the underlying molecular basis for SCA has not been yet uncovered. Unlike other subtypes of SCA, SCA does not have cysts, but why? The newly identified markers by themselves could not fully explain those questions. Given that vimentin and β-catenin localized on the membrane, we inferred that the cell–cell adhesion by these molecules were

---

**FIGURE 2.** Pathological staining for serous cystadenoma of pancreas. (A) H&E stain for Case 1. (B) H&E stain for Case 2. (C) Vimentin staining pattern for the tumor for Case 1, the left bottom panel indicated normal pancreas acinar cell as control. (D) β-Catenin staining pattern for the tumor for Case 1, the left bottom panel indicated normal pancreas acinar cell as control. (E) α-1 Antitrypsin staining pattern for the tumor for Case 1, the left bottom panel indicated normal pancreas acinar cell as control. (F) α-1 Antichymotrypsin staining pattern for the tumor for Case 1, the left bottom panel indicated normal pancreas acinar cell as control. H&E = hematoxylin and eosin.
at least not absent in SSCA. We expect future research to address the difference between SSCA and other types of SCA to a greater extent and depth.

ACKNOWLEDGMENTS

The authors would like to thank Wenying Qiu and Xiaojing Qian from the Department of Anatomy, Histology, and Embryology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, Beijing, China, for their kind support for capturing high-quality images from the immunohistochemistry staining slides. They would also like to thank YiJia Li and Rui Tian from Peking Union Medical College for language editing.

REFERENCES

1. Le Borgne J, de Calan L, Partensky C. Cystadenomas and cystadenocarcinomas of the pancreas: a multiinstitutional retrospective study of 398 cases. French Surgical Association. Ann Surg. 1999;230:152–161.

2. Casadei R, D’Ambra M, Pezzilli R, et al. Solid serous microcystic tumor of the pancreas. J Pancreas. 2008;9:538–540.

3. Kosmahl M, Wagner J, Peters K, et al. Serous cystic neoplasms of the pancreas: an immunohistochemical analysis revealing alpha-inhibin, neuron-specific enolase, and MUC6 as new markers. Am J Surg Pathol. 2004;28:339–346.

4. Perez-Ordonez B, Naseem A, Lieberman PH, et al. Solid serous adenoma of the pancreas. The solid variant of serous cystadenoma? Am J Surg Pathol. 1996;20:1401–1405.

5. Kishida Y, Matsubayashi H, Okamura Y, et al. A case of solid-type serous cystadenoma mimicking neuroendocrine tumor of the pancreas. J Dig Dis. 2014;15:211–215.

6. Le Bodic MF, Heymann MF, Lecomte M, et al. Immunohistochemical study of 100 pancreatic tumors in 28 patients with multiple endocrine neoplasia, type I. Am J Surg Pathol. 1996;20:1378–1384.

7. Notohara K, Hamazaki S, Tsukayama C, et al. Solid-pseudopapillary tumor of the pancreas: immunohistochemical localization of neuroendocrine markers and CD10. Am J Surg Pathol. 2000;24:1361–1371.

8. Yeh TS, Jan YY, Chiu CT, et al. Characterization of oestrogen receptor, progesterone receptor, trefoil factor 1, and epidermal growth factor and its receptor in pancreatic cystic neoplasms and pancreatic ductal adenocarcinoma. Gut. 2002;51:712–716.

9. Lieber MR, Lack EE, Roberts JR Jr et al. Solid and papillary epithelial neoplasm of the pancreas. An ultrastructural and immunocytochemical study of six cases. Am J Surg Pathol. 1987;11:85–93.

10. Burford H, Baloch Z, Liu X, et al. E-cadherin/beta-catenin and CD10: a limited immunohistochemical panel to distinguish pancreatic ductal adenocarcinoma from solid pseudopapillary neoplasm of the pancreas on endoscopic ultrasound-guided fine-needle aspirates of the pancreas. Am J Clin Pathol. 2009;132:831–839.

11. Wu J, Jiao Y, Dal Molin M, et al. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci USA. 2011;108:21188–21193.

12. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010;28:69–76.

13. Mendez MG, Kojima S, Goldman RD. Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J. 2010;24:1838–1851.

14. Chaw SY, Majeed AA, Dalley AJ, et al. Epithelial to mesenchymal transition (EMT) biomarkers—E-cadherin, beta-catenin, APC and Vimentin—in oral squamous cell carcinogenesis and transformation. Oral Oncol. 2012;48:997–1006.

15. Pu J, Tong Q, Zhou C, et al. Serous microcystic adenoma of the pancreatic head: report of two cases and review of the literature. Oncol Lett. 2010;1:723–727.

16. Brembeck FH, Rosario M, Birchmeier W. Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr Opin Genet Dev. 2006;16:51–59.